Funding Performance: How Great Donors Invest in Grantee Success

The Funding Performance campaign encourages funders to rise to the urgency of this moment. You'll find no pie-in-the-sky theory in the resources on this page. Instead, you'll find practical advice about the specific practices that produce outsized progress on urgent issues of our time.The centerpiece of this campaign is Funding Performance: How Great Donors Invest in Grantee Success (2021), a Jim Collins–style monograph intended to generate positive peer pressure among foundations and individual donors.The monograph features insightful essays by eight highly respected thinkers and doers: Hilary Pennington, Ford Foundation; Daniel Stid, Hewlett Foundation; Sam Cobbs, Tipping Point Community; Jeff Bradach and Jeri Eckhart Queenan, Bridgespan; Lowell Weiss, Leap Ambassadors support team; Hilda Polanco and Deborah Linnell, FMA. All of these essayists have vantage points that have given them a close-up look at the best and worst practices in our sector. In Funding Performance, they share both—in the hope of turning this moment of crisis into a moment of truth and then a moment of productive pivot

Meeting Report: Methylmercury in Marine Ecosystems—From Sources to Seafood Consumers

Mercury and other contaminants in coastal and open-ocean ecosystems are an issue of great concern globally and in the United States, where consumption of marine fish and shellfish is a major route of human exposure to methylmercury (MeHg). A recent National Institute of Environmental Health Sciences–Superfund Basic Research Program workshop titled “Fate and Bioavailability of Mercury in Aquatic Ecosystems and Effects on Human Exposure,” convened by the Dartmouth Toxic Metals Research Program on 15–16 November 2006 in Durham, New Hampshire, brought together human health experts, marine scientists, and ecotoxicologists to encourage cross-disciplinary discussion between ecosystem and human health scientists and to articulate research and monitoring priorities to better understand how marine food webs have become contaminated with MeHg. Although human health effects of Hg contamination were a major theme, the workshop also explored effects on marine biota. The workgroup focused on three major topics: a) the biogeochemical cycling of Hg in marine ecosystems, b) the trophic transfer and bioaccumulation of MeHg in marine food webs, and c) human exposure to Hg from marine fish and shellfish consumption. The group concluded that current understanding of Hg in marine ecosystems across a range of habitats, chemical conditions, and ocean basins is severely data limited. An integrated research and monitoring program is needed to link the processes and mechanisms of MeHg production, bioaccumulation, and transfer with MeHg exposure in humans

Patterns of Mercury Deposition and Concentration in Northeastern North America (1996–2002)

Data from 13 National Atmospheric Deposition Program Mercury Monitor Network (NADP/MDN) monitoring stations (1996–2002) and the Underhill (VT) event-based monitoring site (1993–2002) were evaluated for spatial and temporal trends. More precipitation and mercury deposition occurred in the southern and coastal MDN sites, except for the Underhill site, which received more mercury deposition than surrounding sites. Precipitation patterns varied. Regionally, higher concentrations of mercury were recorded during the late spring and summer months. Several sub-regional clusters of MDN sites were evident, based on mercury deposition patterns. In general, more mercury was deposited during the summer months. “Enhanced” weekly deposition (>250 ng/m 2 ) and distinct seasonal deposition patterns were evident at all MDN sites. Regionally, high depositional periods contributed significantly to annual loads (<20%–~60%). Southern and coastal sites measured more frequent periods of high deposition than inland sites. Spring and summer “enhanced” deposition may be important contributing factors to mercury bioaccumulation during the growing season. Recent regional reductions of mercury emissions were not reflected in the regional mercury concentration or deposition data. Few sites showed linear relations between the concentration of mercury in precipitation and acid rain co-contaminants (sulfates and nitrates).Peer Reviewedhttp://deepblue.lib.umich.edu/bitstream/2027.42/44442/1/10646_2004_Article_6258.pd

Meeting Report: Methylmercury in Marine Ecosystems—From Sources to Seafood Consumers

Mercury and other contaminants in coastal and open-ocean ecosystems are an issue of great concern globally and in the United States, where consumption of marine fish and shellfish is a major route of human exposure to methylmercury (MeHg). A recent National Institute of Environmental Health Sciences–Superfund Basic Research Program workshop titled “Fate and Bioavailability of Mercury in Aquatic Ecosystems and Effects on Human Exposure,” convened by the Dartmouth Toxic Metals Research Program on 15–16 November 2006 in Durham, New Hampshire, brought together human health experts, marine scientists, and ecotoxicologists to encourage cross-disciplinary discussion between ecosystem and human health scientists and to articulate research and monitoring priorities to better understand how marine food webs have become contaminated with MeHg. Although human health effects of Hg contamination were a major theme, the workshop also explored effects on marine biota. The workgroup focused on three major topics: a) the biogeochemical cycling of Hg in marine ecosystems, b) the trophic transfer and bioaccumulation of MeHg in marine food webs, and c) human exposure to Hg from marine fish and shellfish consumption. The group concluded that current understanding of Hg in marine ecosystems across a range of habitats, chemical conditions, and ocean basins is severely data limited. An integrated research and monitoring program is needed to link the processes and mechanisms of MeHg production, bioaccumulation, and transfer with MeHg exposure in humans

Post-intervention Status in Patients With Refractory Myasthenia Gravis Treated With Eculizumab During REGAIN and Its Open-Label Extension

OBJECTIVE: To evaluate whether eculizumab helps patients with anti-acetylcholine receptor-positive (AChR+) refractory generalized myasthenia gravis (gMG) achieve the Myasthenia Gravis Foundation of America (MGFA) post-intervention status of minimal manifestations (MM), we assessed patients' status throughout REGAIN (Safety and Efficacy of Eculizumab in AChR+ Refractory Generalized Myasthenia Gravis) and its open-label extension. METHODS: Patients who completed the REGAIN randomized controlled trial and continued into the open-label extension were included in this tertiary endpoint analysis. Patients were assessed for the MGFA post-intervention status of improved, unchanged, worse, MM, and pharmacologic remission at defined time points during REGAIN and through week 130 of the open-label study. RESULTS: A total of 117 patients completed REGAIN and continued into the open-label study (eculizumab/eculizumab: 56; placebo/eculizumab: 61). At week 26 of REGAIN, more eculizumab-treated patients than placebo-treated patients achieved a status of improved (60.7% vs 41.7%) or MM (25.0% vs 13.3%; common OR: 2.3; 95% CI: 1.1-4.5). After 130 weeks of eculizumab treatment, 88.0% of patients achieved improved status and 57.3% of patients achieved MM status. The safety profile of eculizumab was consistent with its known profile and no new safety signals were detected. CONCLUSION: Eculizumab led to rapid and sustained achievement of MM in patients with AChR+ refractory gMG. These findings support the use of eculizumab in this previously difficult-to-treat patient population. CLINICALTRIALSGOV IDENTIFIER: REGAIN, NCT01997229; REGAIN open-label extension, NCT02301624. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that, after 26 weeks of eculizumab treatment, 25.0% of adults with AChR+ refractory gMG achieved MM, compared with 13.3% who received placebo

Minimal Symptom Expression' in Patients With Acetylcholine Receptor Antibody-Positive Refractory Generalized Myasthenia Gravis Treated With Eculizumab

The efficacy and tolerability of eculizumab were assessed in REGAIN, a 26-week, phase 3, randomized, double-blind, placebo-controlled study in anti-acetylcholine receptor antibody-positive (AChR+) refractory generalized myasthenia gravis (gMG), and its open-label extension

Before You Speak

Poster for a staged reading of Before You Speak, written by Jeri Weiss and directed by Les Epstein. The reading was part of the Discovery Staged Reading Series at the June M. McBroom Theater of Community High School.https://digitalcommons.hollins.edu/discovery/1001/thumbnail.jp

Stray Hearts

Poster for a staged reading of Stray Hearts, written by Jeri Weiss and directed by Todd Ristau. The reading was part of the Centerpieces Reading Series on the Waldron Stage of the Mill Mountain Theatre.https://digitalcommons.hollins.edu/centerpieces/1016/thumbnail.jp

Run, Jane, Run

Poster for a staged reading of Run, Jane, Run, written by Jeri Weiss and directed by Todd Ristau. The reading was part of the Centerpieces Reading Series on the Waldron Stage of the Mill Mountain Theatre.https://digitalcommons.hollins.edu/centerpieces/1014/thumbnail.jp